Summary: This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, beta, is localized to chromosome 3 and the alpha form is localized to chromosome 17. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. Alternative splicing of this gene results in two transcript variants; however, the second variant has not yet been fully described. [provided by RefSeq, Jul
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service.
OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at email@example.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
* Delivery time in business days.Occasional delay may occur due to complexity of the constructs.
All shRNA Citations:
Citrullination regulates pluripotency and histone H1 binding to chromatin, Christophorou, MA;Castelo-Branco, G;Halley-Stott, RP;Oliveira, CS;Loos, R;Radzisheuskaya, A;Mowen, KA;Bertone, P;Silva, JC;Zernicka-Goetz, M;Nielsen, ML;Gurdon, JB;Kouzarides, T;,
Nature, Feb 2014.
[Padi4 ] Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy, Ahmad, T;Mukherjee, S;Pattnaik, B;Kumar, M;Singh, S;Kumar, M;Rehman, R;Tiwari, BK;Jha, KA;Barhanpurkar, AP;Wani, MR;Roy, SS;Mabalirajan, U;Ghosh, B;Agrawal, A;,
EMBO J., Feb 2014.
[Miro1] Vaccine-Mediated Immunotherapy Directed Against a Transcription Factor Driving the Metastatic Process, Ardiani, A;Gameiro, SR;Palena, C;Hamilton, D;Kwilas, A;King, TH;Schlom, J;Hodge, JW;,
Cancer Res., Feb 2014.
[Twist1] NFIB-Mediated Repression of the Epigenetic Factor Ezh2 Regulates Cortical Development, Piper, M;Barry, G;Harvey, TJ;McLeay, R;Smith, AG;Harris, L;Mason, S;Stringer, BW;Day, BW;Wray, NR;Gronostajski, RM;Bailey, TL;Boyd, AW;Richards, LJ;,
J. Neurosci., Feb 2014.
[Ezh2] INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) IS UPREGULATED IN THYROID CARCINOMA AND DRIVES THE DEVELOPMENT OF AN IMMUNOSUPPRESSANT TUMOR MICROENVIRONMENT, Moretti, S;Menicali, E;Voce, P;Morelli, S;Cantarelli, S;Sponziello, M;Colella, R;Fallarino, F;Orabona, C;Alunno, A;de Biase, D;Bini, V;Mameli, MG;Filetti, S;Gerli, R;Macchiarulo, A;Melillo, RM;Tallini, G;Santoro, M;Puccetti, P;Avenia, N;Puxeddu, E;,
J. Clin. Endocrinol. Metab., Feb 2014.
[IDO1] SNARE-dependent interaction of Src, EGF receptor and Î²1 integrin regulates invadopodium formation and tumour cell invasion, Williams, KC;Coppolino, MG;,
J. Cell. Sci., Feb 2014.
[ITGB1BP3] Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in the muscle injury model, Yang, Z;Nakagawa, K;Sarkar, A;Maruyama, J;Iwasa, H;Bao, Y;Ishigami-Yuasa, M;Ito, S;Kagechika, H;Hata, S;Nishina, H;Abe, S;Kitagawa, M;Hata, Y;,
Mol. Cell. Biol., Feb 2014.
[WWTR1 ] G Protein-Coupled Receptor Kinase-6 Interacts with Activator of G Protein Signaling-3 To Regulate CXCR2-Mediated Cellular Functions, Singh, V;Raghuwanshi, SK;Smith, N;Rivers, EJ;Richardson, RM;,
J. Immunol., Feb 2014.
[GPSM1] Mitochondrial Targeting of Cytochrome P450 (CYP) 1B1 and its Role in Polycyclic Aromatic Hydrocarbon-Induced Mitochondrial Dysfunction, Bansal, S;Leu, A;Gonzalez, FJ;Guengerich, FP;Roy Chowdhury, A;Anandathheerthavarada, HK;Avadhani, NG;,
J. Biol. Chem., Feb 2014.
[ADX] Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by HB-EGF/EGF Receptor Signaling, Cole, CL;Rushton, G;Jayson, GC;Avizienyte, E;,
J. Biol. Chem., Feb 2014.
* Delivery time is an estimate in business days. Occasional delays may occur due to unforeseen complexities in the preparation of your construct. International customers may expect an additional 1-2 weeks in shipping